Recent developments in mitogen activated protein kinase inhibitors as potential anticancer agents

Area of Science:

• Biochemistry
• Molecular Biology
• Medicinal Chemistry

Background:

• The mitogen-activated protein kinase (MAPK) pathway, including the RAS-RAF-MEK-ERK cascade, is crucial for linking extracellular stimuli to intracellular responses.
• Dysregulation of the MAPK pathway is implicated in various pathological conditions, most notably cancer, driven by genetic mutations or environmental factors.

Purpose of the Study:

• To review the role of heterocyclic scaffolds in inhibiting the MAPK signaling pathway for cancer management.
• To explore recent advancements in MAPK signaling pathway inhibitors, focusing on their mechanisms of action.

Main Methods:

• Literature review of studies on MAPK signaling pathway inhibitors.
• Analysis of heterocyclic compounds (synthetic and natural products) targeting MAPK pathway components.
• Discussion of structure-activity relationships and docking studies for mechanistic insights.

Main Results:

• Heterocyclic compounds containing nitrogen, sulfur, and oxygen exhibit potential in blocking the MAPK signaling pathway.
• These heterocyclics demonstrate high potency and selectivity, with reduced off-target effects.
• Both synthetic compounds and natural products with heterocyclic moieties are effective MAPK inhibitors.

Conclusions:

• Heterocyclic scaffolds are valuable in developing targeted cancer therapies by inhibiting the MAPK pathway.
• Further research into structure-activity relationships and mechanistic studies will aid in designing more effective MAPK inhibitors.